XERS Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Xeris Biopharma Holdings (NASDAQ: XERS)
›
Xeris Biopharma Holdings (NASDAQ: XERS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 435 employees.
The shares were at 16.62 USD on 19 November 2026, up 68.4% over 52 weeks. Its 52-week range is 5.250 USD to 17.28 USD: the price is 3.8% below the high and 216.6% above the low.
Its market capitalisation is 3.04B USD.
Xeris Biopharma Holdings reports return on equity of 4.0%, an operating margin of 12.7% and revenue up 44.2% year over year.
Its debt exceeds its cash by 94.98M USD, a debt-to-equity ratio of 18.85. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.29 USD is 4.0% above the current price. The next earnings report is expected on 4 March 2027.